This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NRC OKs Exelon Takeover of Constellation: Hot Trends

Stocks in this article: EXC CEG VVUS

NEW YORK ( TheStreet) -- Exelon (EXC) is trending Friday as the Nuclear Regulatory Commission approved the company's proposed $7.9 billion takeover of Constellation Energy Group (CEG).

The NRC said staff and management at Constellation Energy Nuclear Group's plants would remain unchanged when Exelon takes over. The deal has already been approved by the Justice Department, both companies' shareholders and New York and Texas regulators.

Constellation's nuclear division operates reactors in Maryland and New York, and both companies own plants in Texas, where Constellation also markets power and gas. Maryland regulators are expected to announce whether the state will give approval to the deal Friday.

Anglo-American is another poplar search as the mining company posted record operating profit for 2011 on strength from its coal and diamond operations.

The company reported operating profit of $11.1 billion, a 14% increase from a year before. The company noted three major projects completed in 2011 -- a South African iron ore mine, expansion of a Chilean copper mine and nickel operations in Brazil. The company also reported operating profit for its biggest sector -- iron ore and manganese -- rose 23%.

Anglo American said its long-term outlook for its diversified mix of commodities remains strong.

Qnexa is trending as the diet drug is being reviewed by the Federal Drug Administration after the agency rejected the drug in 2010.

The FDA, which rejected the drug amid safety concerns, including risk of birth defects and cardiovascular problems, is now being presented with additional data from the drug's manufacturer Vivus (VVUS). If the FDA approves the drug, it will be the first new prescription diet pill in 13 years. The FDA is expected to release its analysis of the new data on Qnexa on Friday.

The chatter on Main Street (a.k.a. Google, Yahoo! and other search sites) is always of interest to investors on Wall Street. Thus, each day, TheStreet compiles the stories that are trending on the Web, and highlights the news that could make stocks move.

-- Written by Brittany Umar.

Brittany joined TV in November 2006 after completing a degree in Journalism and Media Studies at Rutgers College. Previously, Brittany interned at the local ABC affiliate in New York City WABC-TV 7 where she helped research and produce On Your Side, a popular consumer advocacy segment.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs